

Patient Name:
DOB:
Date of Last Infusion
Insurance:

Clinic Location:
Merrimack, NH $\Box$
Concord, NH $\square$

## Cimzia® (certolizumab pegol) Treatment Orders

Diagno	osis:		
□M05	5.79 RA w/rheumatoid factor, multiple s	sites	
	5.60 Rheumatoid arthritis of unspecified	site $\qed$ M05.70 Rheumatoid arthritis with rheumatoid factor	
	n involvement of organs and systems	of unspec site w/o organ or systems involvement	
	.50 Arthropathic psoriasis, unspecified	☐ L40.59 Other psoriatic arthropathy	
☐ M4. spir	5.9 Ankylosing spondylitis of unspec sites ne	in	
☐ L40	.0 psoriatic vulgaris (plaque psoriasis)	☐ L40.8 other psoriasis ☐ L40.9 psoriasis, unspecified	
Other	:(ICD-10 and description		
	(ICD-10 and description	1)	
lursing C	rders:		
$\checkmark$	Hold treatment and notify provide	er for:	
	o Signs or symptoms of illness o	or active infection	
	o Cough, night sweats, unexplai		
	o Planned/recent surgical proce	_	
	o Neurological changes		
	o Recent live vaccinations		
ab Ordei			
	w/diff, CMP, ESR, CRP every 8 wee	ake	
∐ Qua	ntiferon TB Gold once per year; ta	rget collection date:	
☐ Oth	er:		
Initial ( On <u>\</u>	<b>Dosing</b> <u>Week 0</u> , <u>Week 2</u> and <u>Week 4</u> admir	nister <b>Cimzia 400 mg</b> (given as 2 subcutaneous	
ır	njections of 200 mg).		
Mainte	enance Dosing		
	_	<b>0 mg</b> (given as 2 subcutaneous injections of 200 mg).	
	_		
	equency: $\square$ Repeat every 2 w	veeks Repeat every 4 weeks	
	vation Period:		
oxdot Following <u>initial</u> Cimzia treatment, observe patient for 15 minutes for hypersensitivity. Patient			
	who have previously tolerated Cimzia do not require observation period.		
☑	If hypersensitivity reaction occurs, initiate Hypersensitivity Reaction Management Policy/Protocol as clinically indicated.		
dering Pro	ovider: (please print):		
ovider signature:		Date:	